Targeting non-muscle myosin II promotes corneal endothelial migration through regulating lamellipodial dynamics
Corneal endothelial cell (CEC) dysfunction causes corneal edema that may lead to blindness. In addition to corneal transplantation, simple descemetorhexis has been proposed to treat centrally located disease with adequate peripheral cell reserve, but promoting the centripetal migration of CECs is pivotal to this strategy. Here, we show that targeting non-muscle myosin II (NMII) activity by Y27632, a ROCK inhibitor, or blebbistatin, a selective NMII inhibitor, promotes directional migration of CECs and accelerates in vitro wound healing. The lamellipodial protrusion persistence is increased, and actin retrograde flow is decreased after NMII inhibition. Counteracting lamellipodial protrusion by actin-related protein 2/3 (ARP2/3) inhibitor abolishes this migration-promoting effect. Although both Y27632 and blebbistatin accelerate wound healing, cell junctional integrity and barrier function are better preserved after blebbistatin treatment, leading to more rapid corneal deturgescence in rabbit corneal endothelial wounding model. Our findings indicate that NMII is a promising therapeutic target in the treatment of CEC dysfunction.
NMII inhibition promotes directional migration and wound healing of CECs in vitro.
Lamellipodial protrusion persistence is increased after NMII inhibition.
Selective NMII inhibitor preserves junctional integrity better than ROCK inhibitor.
Selective NMII inhibitor accelerates corneal deturgescence after wounding in vivo.
KeywordsCorneal endothelial cell Non-muscle myosin II Cell migration Wound healing Lamellipodia
We are grateful to the Microscopy Core Facility, Department of Medical Research, National Taiwan University Hospital and National Taiwan University Molecular Imaging Center for providing the instrumentation for this study. We also thank Ms. Yung-Ching Wang for technical support.
This study is supported by funding from the Taiwan Ministry of Science and Technology (MOST 105-2628-B-418-001-MY3 and MOST 107-3017-F-002-002) and TVGH-NTUH Joint Research Program (VN105-1, VN106-05, and VN107-15).
Compliance with ethical standards
Use of animal and the experimental procedures were in accordance with the principles of the Association for Research in Vision and Ophthalmology Statement for Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committee of the National Taiwan University Hospital.
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.Lass JH, Gal RL, Dontchev M, Beck RW, Kollman C, Dunn SP, Heck E, Holland EJ, Mannis MJ, Montoya MM et al (2008) Donor age and corneal endothelial cell loss 5 years after successful corneal transplantation. Specular microscopy ancillary study results. Ophthalmology 115:627–632.e628CrossRefGoogle Scholar
- 22.Wang TJ, Wang IJ, Lu JN, Young TH (2012) Novel chitosan-polycaprolactone blends as potential scaffold and carrier for corneal endothelial transplantation. Mol Vis 18:255–264Google Scholar
- 33.Doller A, Badawi A, Schmid T, Brauss T, Pleli T, zu Heringdorf DM, Piiper A, Pfeilschifter J, Eberhardt W (2015) The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking. Exp Cell Res 330:66–80CrossRefGoogle Scholar
- 39.Ichijima H, Petroll WM, Barry PA, Andrews PM, Dai M, Cavanagh HD, Jester JV (1993) Actin filament organization during endothelial wound healing in the rabbit cornea: comparison between transcorneal freeze and mechanical scrape injuries. Invest Ophthalmol Vis Sci 34:2803–2812Google Scholar